Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Liver Cancer · 29.03.2024 · 1-11
DOI: 10.1159/000538627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 29.03.2024. Verfasst von Keiichi Akahoshi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Recent advances in systemic therapy for hepatocellular carcinoma (HCC) have led to debates about the feasibility of combination therapies, such as systemic therapy combined with surgery or transarterial chemoembolization, for patients with advanced HCC. However, a lack of consensus on the oncological resectability criteria has hindered discussions of “conversion therapy” and the optimal management in patients with HCC. To address this issue, the Japan Liver Cancer Association (JLCA) and the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) established a working group and discussed the concept of borderline resectable HCC. Herein, we present a consensus statement from this expert panel on the resectability criteria for HCC from the oncological standpoint under the assumption of technically and liver-functionally resectable situations. The criteria for oncological resectability in HCC are classified into three grades: resectable, representing an oncological status for which surgery alone may be expected to offer clearly better survival outcomes as compared with other treatments; borderline resectable 1, representing an oncological status for which surgical intervention as a part of multidisciplinary treatment may be expected to offer survival benefit; and borderline resectable 2, representing an oncological status for which the efficacy of surgery is uncertain and the indication for surgery should be determined carefully under the standard multidisciplinary treatment. These criteria aim to provide a common language for discussing and analyzing the treatment strategies for advanced HCC. It is also expected that these criteria will be optimized, modified, and updated based on further advancements in systemic therapies and future validation studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.
- Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
- Department of Surgery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
- Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
- Department of Surgery, Kansai Medical University, Osaka, Japan.
Zitieren
APA
Akahoshi, K., Shindoh, J., Tanabe, M., Ariizumi, S., Eguchi, S., Okamura, Y., Kaibori, M., Kubo, S., Shimada, M., Taketomi, A., Takemura, N., Nagano, H., Nakamura, M., Hasegawa, K., Hatano, E., Yoshizumi, T., Endo, I., & Kokudo, N. (2024). Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023. Liver Cancer, 1-11. https://doi.org/10.1159/000538627
Vancouver
Akahoshi K, Shindoh J, Tanabe M, Ariizumi S, Eguchi S, Okamura Y, et al. Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023. Liver Cancer. 2024:1-11. doi:10.1159/000538627
BibTeX
@article{Akahoshi2024,
author = {Akahoshi, Keiichi and Shindoh, Junichi and Tanabe, Minoru and Ariizumi, Shunichi and Eguchi, Susumu and Okamura, Yukiyasu and Kaibori, Masaki and Kubo, Shoji and Shimada, Mitsuo and Taketomi, Akinobu and Takemura, Nobuyuki and Nagano, Hiroaki and Nakamura, Masafumi and Hasegawa, Kiyoshi and Hatano, Etsuro and Yoshizumi, Tomoharu and Endo, Itaru and Kokudo, Norihiro},
title = {Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023},
journal = {Liver Cancer},
year = {2024},
pages = {1--11},
doi = {10.1159/000538627}
}
EUVIMED